
All		Group NA	Product COMMERCIAL
Clinic: All Primary Care Specialty: All		Entity All	Condition OVERALL
TCOC Summary Dashboard Rolling 12 Months: April through March - 2020, 2021, 2022	-Risk Adjusted Total Cost of Care Metrics -Total Spend including Clinics, Hospitals, RX and Referral Partners - Total Reimbursment Capped at \$125,000 -Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+	Clinic All	Specialty All


See Trend

TCOC Summary		See Trend O
TCI	Price	RUI
1.029 40.003	1.06 40.02	0.98 V -0.01
Member Count Avg ACG Total PMPM - Risk Adj Total Spend Members Over \$125K	175,690 0.98 \$603 \$1,309,730,834 1,005	In System Out of System

Place of Service Summary



Utilization Metrics			See Trend
High Cost		Patient Management	
Admits	1.01	E&M Primary Care	1.02
IP Surgery	1.08	E&M Specialty Care	0.81
Emergency Department	1.08	Laboratory/Pathology	0.95
Outpatient Surgery	1.08	,, 3,	
Hightech Radiology (ER)	1.07	Standard Radiology	1.00
Hightech Radiology (Non-ER)	1.00	RX Count	1.02



HealthPartners

Condition Summary

	Member Count	Avg ACG	тсі	Price	RUI	Total PMPM
OVERALL	175,690	0.98	1.03	1.06	0.98	\$592
ALL OTHER CONDITIONS	97,258	0.51	1.01	1.03	0.97	\$315
ARTHRITIS	7,442	2.18	1.12	1.08	1.03	\$1,686
ASTHMA	11,570	1.71	1.05	1.06	0.99	\$1,011
BACK PAIN	28,501	1.73	1.02	1.06	0.96	\$1,028
CHF	720	4.91	1.02	1.08	0.94	\$4,127
CHRONIC RENAL FAILU	1,559	4.30	1.02	1.08	0.94	\$2,559
COPD	1,076	3.54	1.08	1.11	0.97	\$2,394
DEPRESSION	22,288	2.03	1.02	1.05	0.97	\$1,134
DIABETES	8,618	2.22	1.02	1.07	0.95	\$1,431
HYPERLIPIDEMIA	23,733	1.78	1.06	1.08	0.98	\$1,064
HYPERTENSION	25,617	1.87	1.06	1.08	0.98	\$1,194
ISCHEMIC HEART DISE	2,794	3.20	1.06	1.09	0.96	\$2,341
OVERALL - PEDS	51,341	0.51	0.97	1.04	0.98	\$304
ALL OTHER CONDITION	19,231	0.21	0.93	1.02	0.91	\$116
AD INSTMENT DISODD						

All		Group NA	Product COMMERCIAL
Clinic: All Primary Care Specialty: All		Entity All	Condition OVERALL
TCOC Opportunity Summary	-Risk Adjusted Total Cost of Care Metrics -Total Spend including Clinics, Hospitals, RX and Referral Partners - Total Reimbursment Capped at \$125,000	Clinic	Specialty
Rolling 12 Months: April 2021 through March 2022	-Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+	All	All

Total Cost of Care	Members	Total Spend	Total Cost Index	Dollar Reduction (1pt or 1.00)
	175,690	\$1,181M	1.03	\$34,000,000
Price Opportunity			Price Index	Dollar Reduction (1 pt or 1.00)
			1.06	\$65,000,000
Fee Schedule Opportunity	% 0	f Total Spend	Price	Dollar Reduction (1 pt or 1.00)
Professional		44.4%	1.01	\$2,550,000
Primary Care		10.5%		
		2.8%		
		2.1%		
		1.1%		
Specialty Care		32.7%		
		2.8%		
		2.2%		
		1.9%		
Inpatient		16.3%	1.03	\$11,000,000
		7.4%		
		5.0%		
		2.7%		
Outpatient		27.0%	1.20	\$57,000,000
		6.9%		
		5.1%		
		3.2%		

Price Opportunity Detail

	Total	OP Hosp	% of Procs	Total
	Procedures	Procedures	in Surg Ctr	Opportunity
Total OP Surgery Opportunity	24,780	13,013	47%	\$39,000,000
COLONOSCOPY AND BIOPSY	3,005	1,517	50%	\$2,200,000
TLH W/T/O 250 G OR LESS	216	213	1%	\$1,700,000
KNEE ARTHROSCOPY/SURGERY	749	240	68%	\$1,500,000
COLONOSCOPY W/LESION REMOVAL	2,290	1,186	48%	\$1,200,000
NJX INTERLAMINAR LMBR/SAC	291	211	27%	\$1,000,000

Resource Use Opport	unity		RUI Index	Dollar Reduction (1 pt or 1.00)
			0.98	\$13,000,000
Utilization Opportunity	Actual Utilization	Utilization Improvement to 1.00	RUI	Dollar Reduction to Avg (1.00)
High Cost Utilization Measures				
Admits	8,020	84	1.01	\$1,600,000
IP Surgery	1,852	145	1.08	\$5,200,000
Emergency Department	28,758	2,105	1.08	\$3,050,000
Outpatient Surgery	28,326	2,160	1.08	\$9,600,000
Hightech Radiology (ER)	8,950	582	1.07	\$255,000
Hightech Radiology (Non-ER)	33,514	0	1.00	\$0
Patient Management Utilization Measures				
E&M Primary Care	404,554	9,116	1.02	\$2,000,000
E&M Specialty Care	382,903	0	0.81	\$0
Laboratory/Pathology	1,508,245	0	0.95	\$0

176,340

2,005,043

0

40,192

1.00

1.02

\$0

\$2,750,000

HealthPartners

Resource Opportunity Details


Standard Radiology

RX Count

Results below are entity level and are <u>NOT CLINIC SPECIFIC</u> regardless of selection above.	Actual Utilization	Utilization Improvement to 1.00	Index	Dollar Reduction to Avg(1.00)
Admits*				
Orthopedics	556	-78	1.35	\$3,364,000
Respiratory	832	-70	1.27	\$1,985,000
Circulatory	549	-42	1.26	\$1,652,000
Infectious/Parasitic	406	-15	1.21	\$471,000
Mental Health	612	-9	1.18	\$167,000
Outpatient Surgery*				
COLONOSCOPY AND BIOPSY	8,321	-578	1.25	\$863,000
INSERT CATHETER/ SPINE STIM, INJE	1,462	-411	1.62	\$963,000
DEBRIDE WOUND/INFECTION/BURN	452	-291	3.27	\$469,000
DECOMPRESSION PERIPHERAL NERVE	396	-162	1.97	\$424,000
NON-OR THR NERVOUS SYSTEM PRO	646	-122	1.44	\$209,000
*ACO SmartCare Flag does not apply				

6.0 \sim . .: ... c

Total Cost of Care Overview for			HealthPartners
All		Group NA	Product COMMERCIAL
Clinic: All		Entity All	Condition OVERALL
Trended Utilization	-Risk Adjusted Total Cost of Care Metrics -Total Spend including Clinics, Hospitals, RX and Referral Partners - Total Reimbursment Capped at \$125,000	Clinic All	Metro Expected
Rolling 12 Months: April through March - 2020, 2021, 2022	-Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+	711	Rate per 1000



All

Trended Utilization - Hospital IP/OP

Rolling 12 Months: April through March - 2020, 2021, 2022

INPATIENT

Total Procs/1000: 40.10

	Procs per 1000	Units to Avg	Index
Orthopedics	2.78	-78	1.2
Respiratory	4.16	-70	1.1
Circulatory	2.75	-42	1.1
Infectious/Parasitic	2.03	-15	1.0
Mental Health	3.06	-9	1.0
Male Reproductive	0.16	-8	1.3
Nervous	1.90	-7	1.0
Skin & Subcutaneous Tissue	0.57	-7	1.1
Newborns	0.02	-1	1.5
Eye	0.04	0	1.0
Endocrine, Nutritional, Meta	1.25	1	1.0
Trauma	0.12	2	0.9
Other Factors	0.08	3	0.8
Digestive	2.80	4	1.0
Female Reproductive	0.43	4	1.0
Maternity	13.53	6	1.0
Intubation and Ventilation	0.30	7	0.9
Chemical Dependency	0.59	10	0.9
Liver & Pancreas	1.13	10	1.0
Transplant	0.06	12	0.5
Kidney/Urinary	0.87	13	0.9
ENT	0.26	17	0.8
Blood Diseases	0.24	18	0.7
Injuries/Poisonings	0.66	18	0.9
Myeloproliferative	0.36	37	0.7



Group Condition OVERALL NA -Risk Adjusted Total Cost of Care Metrics Service Category -Total Spend including Clinics, Hospitals, RX and Referral Partners Entity INPATIENT - Total Reimbursment Capped at \$125,000 All -Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+ Metro Expected Procs per 1000 Rate/1000 over time Categories with fewer than 3 procedures or admits are not displayed Procs per 1000 5.00 Orthopedics -78 4 2.78 2.39 4.0 Procs per 1000 3.82 3.5 Respiratory -70 3.0 2.35 2.5 3.80 Procs per 1000 3.5 3.40 Circulatory -42 2.4 Procs per 1000 2.16 Infectious/P.. -15 2.0 2.00 1.8 Procs per 1000 3.5 Mental Health -9 3.06 3.0 2.89 0.20 Procs per 1000 0.16 Male -8 0.15 Reproductive 0.11 0.10 ocs per 1000 2.35 2.4

201903

201904

201902

202001 20202 202003 202101 202102 202103 202104 202201

202004

-7

Nervous


			•••
All		Group NA	Product COMMERCIAL
Clinic: All Primary Care Specialty: All		Entity All	Condition OVERALL
Place of Service Opportunity	-Risk Adjusted Total Cost of Care Metrics -Total Spend including Clinics, Hospitals, RX and Referral Partners - Total Reimbursment Capped at \$125,000	Clinic	Specialty All
Rolling 12 Months: April 2021 through March 2022	-Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+	All	All

Outpatient vs. Ambulatory Surgery Center Opportunity *Click on a procedure to limit OP Hospitals


Top OP Procedures to Shift to ASC Total Opportunity - \$39,000,000

	Total OP Surg Procedures	OP Hosp Procedures	% of Procs in Surg Ctr	Total Opportunity
Grand Total	24,780	13,013	47%	\$39,000,000
COLONOSCOPY AND BIOPSY	3,005	1,517	50%	\$2,200,000
TLH W/T/O 250 G OR LESS	216	213	1%	\$1,700,000
KNEE ARTHROSCOPY/SURGERY	749	240	68%	\$1,500,000
COLONOSCOPY W/LESION REMOVAL	2,290	1,186	48%	\$1,200,000
NJX INTERLAMINAR LMBR/SAC	291	211	27%	\$1,000,000
EGD BIOPSY SINGLE/MULTIPLE	1,488	792	47%	\$995,000
LAPAROSCOPIC CHOLECYSTECTOMY	227	182	20%	\$930,000
CREATE EARDRUM OPENING	413	251	39%	\$715,000
SHO ARTHRS SRG RT8TR CUF RPR	180	78	57%	\$680,000
CYSTO/URETERO W/LITHOTRIPSY	209	147	30%	\$650,000
LOW BACK DISK SURGERY	139	83	40%	\$625,000
LAP ING HERNIA REPAIR INIT	136	104	24%	\$610.000

Top Outpatient Hospitals *Click on a hospital to limit OP procedures



HealthPartners





Total Cost of Cale Overview for			•••
All		Group NA	Product COMMERCIAL
Clinic: All Primary Care Specialty: All		Entity All	Condition OVERALL
Referral Partners - Profess	ional - Tatal Reimbursement -	Non Risk Adjusted, Non Capped	Specialty
Rolling 12 Months: April 2021 through March 2	Attaile to d. Communical, Constitution to En		All

Care

8.3%

6.0%

4.8%

6.7%

6.7%

8%

6%

4.0%

3.3%

4%

% of Total Total Spend

3.0%

2.8% 2.7% Grand

Total

12.4%

8.8%

3.7%

Primary Specialty

Care


25.2%


17.6%

0.2%

Primary Care 24% 5592M Specialty Care 76% Performance Results Provider: All Care Type: All Specialty:

Visit Type: All





Professional Partners

*Click on provider to limit panels to the right

ANESTHESIOLOGY

GASTROENTEROLOGY

EMERGENCY MEDICINE

HEMATOLOGY/ONCOLOGY

LABORATORY

0%

2%

OBSTETRICS & GYNECOLOGY

Provider Spend Distribution

Specialty Care Providers

OFFICE VISITS-MENTAL HEALTH

Service Type

OFFICE VISITS-MEDICAL

ANESTHESIOLOGY

MICROBIOLOGY

PHYS EXAMS-ADULTS

IMMUNIZATIONS

OP MENTAL HEALTH

CT/MRI

PROF ADMIN DRUGS - INJECT/IV

HOSPITAL/INSTITUTIONAL VISITS 5%

9	6 of Spend	% of Visits
	8.4%	5.9%
	6.1%	6.1%
	4.9%	1.4%
	4.2%	2.3%
	3.1%	1.5%
	3.0%	2.7%
	2.4%	0.9%
	2.4%	1.2%
	2.2%	2.4%
	2.1%	0.8%
	1.7%	0.9%
	1.6%	0.5%
	1.6%	1.5%
	1.5%	7.5%

A Health Partners

21%

1%

2%

3%

2%

2%

3%

4%

5%

10% 20% 30%

% of Visits

9%

5%

5%

4%

4%

4%

3%

3%

3%

0% 10% 20%

% of Spend

23%

Total Cost of Care Overview for			HealthPartners
All	Top N	l Group	Product
	All	NA	COMMERCIAL
Clinic: All	Visit	Type Entity	Condition
Primary Care Specialty: All	All	All	OVERALL
Referral Partners - Hospital	- Total Reimbursement - Non Risk Adjusted, Non -Attributed, Commercial, Continuously Enrolled, Excluding Babies a		Specialty All

Rolling 12 Months: April 2021 through March 2022

$ \frac{1}{1} 1$	828	Hospital Providers by Spend		See Hospital Table	Treatment Ca	ategory	Spend				
INPATIENT 37.6% O.2% O.6% O.2% Prescription Spend of Spend Adm. Surg Visits Other 0.76% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% Pregnancy, with delivery \$32,328,907 59% \$0.5% 0.5% 0.7% 7 Performance Results Place of Service: All Hospital: All 5.6% 3.4% 4.3% \$17,275,212 72% 62.1% 0.3% 5.6% 4.0% 5.6% 4.0% 5.6% 3.4% 4.3% \$17,275,212 72% 62.1% 0.3% 5.6% 4.0% 5.6% 4.0% 5.6% 5.6% 5.1% 5.1% 5.6% 5.6% 5.1% 5.6% 5.1% 5.1% 5.1% 5.6% 5.1% 5.1% 5.6% 5.1% 5.1% 5.1% 5.6% 5.1% 5.1% 5.6% 5.1% 5.6% 5.6% 5.1% 5.6% 5.1% 5.6% 5.6% 5.1% 5.6% 5.6% 5.6% 5.6%		% of Spend	% of Visits	% of Surgeries		Hospital	Hosp %		OP		All
\$\$778M 0.3% 0.5%		0.2%	0.6%	0.2%	ETG Description			Admi	Surg		Other
62.4% 10.3% 9.2% 9.0% Malignant neoplasm \$18,830,868 59% 4.6% 13.1% 0.6% 4.0% Performance Results 8.2% 7.1% 3.6% 3.6% 0ther infectious diseases \$17,275,212 72% 62.1% 0.3% 5.6% 4.0% 5.6% 4.0% 5.6% 5.6% 3.4% 4.3% 15chemic heart \$17,275,212 72% 62.1% 0.3% 5.6% 4.0% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6%	\$578M	0.3%	0.3%	0.3%		\$32,328,907	59%	50.2%	0.5%	0.7%	7.8%
Performance Results Other infectious \$17,275,212 72% 62.1% 0.3% 5.6% 4. Place of Service: 3.6% 3.4% 4.3% Ischemic heart \$17,022,653 76% 39.7% 14.0% 5.3% 17 All Hospital: 3.1% 4.7% 4.7% 2.2% Joint degeneration, localized - back \$16,487,030 54% 24.5% 20.3% 1.3% 8		10.3%	9.2%	9.0%		\$18,830,868	59%	4.6%	13.1%	0.6%	40.3%
Place of Service: 5.6% 3.4% 4.3% All Ischemic heart \$17,022,653 76% 39.7% 14.0% 5.3% 17 All Visit Category: 4.7% 4.7% 2.2% Joint degeneration, localized - back \$16,487,030 54% 24.5% 20.3% 1.3% 8		8.2%	7.1%	3.6%	Other infectious	¢17 275 212	7204	62 104	0.204	E 604	4.7%
Hospital: All 5.3% 0.8% 2.1% Ischenic heart disease \$17,022,653 76% 39.7% 14.0% 5.3% 17 Visit Category: All 4.7% 4.7% 2.2% Joint degeneration, localized - back \$16,487,030 54% 24.5% 20.3% 1.3% 8		5.6%	3.4%	4.3%	diseases	φ17,275,212	/ 2 /0	02.170	0.370	5.070	4.770
All 24.5% 24.5% 24.5% 20.3% 1.3% 8	Hospital:	5.3%	0.8%	2.1%		\$17,022,653	76%	39.7%	14.0%	5.3%	17.5%
	All	4.7%	4.7%	2.2%		\$16,487,030	54%	24.5%	20.3%	1.3%	8.2%
AII 0.2% 0.0% 0.0%		0.2%	0.0%	0.0%	Septicemia	\$15,712,370	91%	89.6%		1.1%	0.7%

Visit Category

	% of Spend	% of Visits
OFFICE O/P EST MOD 30-39 MIN	3.7%	3.7%
EMERGENCY DEPT VISIT	3.7%	1.2%
OFFICE O/P EST LOW 20-29 MIN	3.1%	4.7%
PSYTX W PT 60 MINUTES	1.3%	2.4%
HUMIRA(CF)	1.1%	0.1%
PREV VISIT EST AGE 40-64	1.0%	0.7%
SCR MAMMO BI INCL CAD	0.9%	0.8%
OFFICE O/P NEW MOD 45-59 MIN	0.9%	0.6%

Procedure

		% of S	pend	% o	fVisits
Hospital Category	0%	5%	10%	0% 5%	10% 15%
OFFICE VISITS-MEDICAL			9.5%		11.6%
HOSPITAL/INSTITUTIONAL VISITS		5.2	%	2.2%	
PROF ADMIN DRUGS - INJECT/IV		3.4%		0.4%	
CT/MRI		2.9%		1.2%	
CHRONIC INFLAMMATORY DISEASE		2.5%		0.3%	
PROF ADMIN DRUGS - CHEMO		2.4%		0.1%	
ANESTHESIOLOGY	2	2.2%		0.9%	
Maternity	2	2.1%		0.1%	
MICROBIOLOGY	2	2.1%		4.9	9%

тсі	U
IP	OP
1.06	1.29
Price	
1.03	1.20
RUI	
1.03	1.08

All

Clinic: All Primary Care Specialty: All

RX Prescribing Summary

Rolling 12 Months: April 2021 through March 2022

	147

Performance Results

Primary/Specialty: Overall

Therapy Class: All Classes

Metro % Generi	с
Primary Care	96%
Specialty Care	91%
Overall	94%
ТСІ	See RX Tr
	0.9
RX Count	1.0

6

RX Drug Category Distribution		See Form/Non Table	•	Therapy Class		
		Total Spend	Scripts	Cost/Rx		Scrip
Primary	Total	\$39,113,332	1,401,127	\$40	CHRONIC INFLAMMATOR	12,42
Care	Formulary	\$36,986,218	1,384,751	\$39	DIABETES	114,52
	Non-Formulary	\$2,127,114	16,376	\$130	5	,=
Specialty	Total	\$99,940,949	603,916	\$200	DERMATOLOGY	46,29
Care	Formulary	\$90,739,760	588,142	\$190	ONCOLOGY	7,84
	Non-Formulary	\$9,201,189	15,774	\$587		,,0
Overall		\$177,655,691	2,005,043	\$89	MULTIPLE SCLEROSIS	1,29
Overall	Formulary	\$166,275,435	1,972,893	\$84	OTHER	109,79
	Non-Formulary	\$11,380,256	32,150	\$354	STIMULANTS	67.69

	Scripts	% of Scripts	Cost/Rx	% of Spend	Total Spend	Scripts/ Person
CHRONIC INFLAMMATOR	12,429	0.62%	\$3,310	23.4%	\$32,555K	9.0
DIABETES	114,521	5.71%	\$238	10.8%	\$14,976K	16.1
DERMATOLOGY	46,298	2.31%	\$291	8.5%	\$11,873K	2.2
ONCOLOGY	7,846	0.39%	\$1,475	8.3%	\$11,572K	7.8
MULTIPLE SCLEROSIS	1,294	0.06%	\$6,329	5.2%	\$7,290K	9.8
OTHER	109,794	5.48%	\$62	4.7%	\$6,593K	3.7
STIMULANTS	67,699	3.38%	\$171	4.1%	\$5,668K	8.6
ASTHMA	72,187	3.60%	\$132	3.8%	\$5,333K	5.0

Top Drugs	Total Spend	Scripts	Cost/Rx	Scripts/ Person	% of Spend	% of Scripts
Overall	\$177,655,691	2,005,0	\$89	19.7	100.00%	100.00%
HUMIRA(CF)	\$19,165,364	2,842	\$6,744	8.9	10.8%	0.1%
ENBREL	\$7,928,559	1,428	\$5,552	9.0	4.5%	0.1%
OZEMPIC	\$4,936,753	6,450	\$765	6.8	2.8%	0.3%
adderall	\$4,302,689	18,218	\$236	7.1	2.4%	0.9%
TRULICITY	\$4,295,641	5,253	\$818	8.7	2.4%	0.3%
HUMIRA	\$3,904,399	633	\$6,168	8.1	2.2%	0.0%
COSENTYX	\$3,659,476	616	\$5,941	7.3	2.1%	0.0%
JARDIANCE	\$3,360,388	6,445	\$521	7.1	1.9%	0.3%
lantus	\$3,258,134	10,355	\$315	8.9	1.8%	0.5%
NORDITROPIN	\$3,048,410	731	\$4,170	12.0	1.7%	0.0%
DUPIXENT	\$3,041,539	975	\$3,120	7.8	1.7%	0.0%
SKYRIZI	\$2,938,282	468	\$6,278	8.4	1.7%	0.0%
AUBAGIO	\$2,865,920	362	\$7,917	9.5	1.6%	0.0%
concerta	\$2,799,488	6,990	\$400	6.1	1.6%	0.3%
HUMALOG	\$2,653,079	5,322	\$499	8.0	1.5%	0.3%
STELARA	\$2,560,982	214	\$11,967	3.1	1.4%	0.0%

Metro Top Drugs

Drug Name	Metro Cost/RX	Metro Scripts/ Person	Metro % of Spend	d Metro % of Scripts
Overall	\$95	19.7	100.0%	100.0%
HUMIRA(CF)	\$6,882	8.4	9.9	9% 0.1%
ENBREL	\$5,579	8.5	4.1%	0.1%
OZEMPIC	\$776	6.8	2.7%	0.3%
adderall	\$240	7.1	2.6%	1.0%
HUMIRA	\$6,320	8.7	2.3%	0.0%
TRULICITY	\$820	8.7	2.3%	0.3%
COSENTYX	\$6,096	8.1	2.2%	0.0%
TRIKAFTA	\$22,417	10.9	2.0%	0.0%
NORDITROPIN	\$4,292	11.3	1.9%	0.0%
lantus	\$299	8.9	1.8%	0.6%
STELARA	\$11,279	3.2	1.7%	0.0%
DUPIXENT	\$3,119	8.2	1.7%	0.1%
HUMALOG	\$474	8.2	1.6%	0.3%
JARDIANCE	\$523	7.0	1.6%	0.3%
SKYRIZI	\$6,213	8.6	1.5%	0.0%
concerta	\$407	6.1	1.5%	0.3%
	****		0% 5% 10%	0% 2% 4%

HealthPartners

See Therapy Class Table

0

Group	Product
NA	COMMERCIAL
Entity	Condition
All	OVERALL
Clinic	Specialty
All	All

- Attributed Members with an RX benefit - Non-Risk Adjusted, Non Capped

-Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+

c \sim

Total Cost of Care Overview for			HealthPartners
All		Group NA	Product COMMERCIAL
Clinic: All		Entity	Condition
Primary Care Specialty: All		All	OVERALL
High Cost Detail	-Total Spend including Clinics, Hospitals, RX and Referral Partners	Clinic	Specialty
	-Attributed, Commercial, Continuously Enrolled, Excluding Babies and 65+	All	All

Rolling 12 Months: April through March - 2020, 2021, 2022

High Cost Distribution




Members Over \$125,000

High Cost by Condition Category

	Member Count	% of Spend	Total Spend	Avg Spend per Member	
Grand Total	1,005	100%	\$254,475K	\$253,209	
CANCER	365	29%	\$73,294K	\$200,806	
NEUROLOGY	471	11%	\$26,924K	\$57,163	
CARDIOLOGY	653	10%	\$25,853K	\$39,591	
INFECTIOUS DISEASES	337	9%	\$21,991K	\$65,254	
ORTHOPEDIC AND ARTHRITIC	649	8%	\$20,562K	\$31,683	
GASTROENTEROLOGY	586	6%	\$15,082K	\$25,737	
PSYCHIATRY/CHEMICAL DEPE	570	5%	\$12,893K	\$22,619	
PULMONOLOGY	455	4%	\$9,604K	\$21,109	
ENDOCRINOLOGY	597	4%	\$9,246K	\$15,488	
NEPHROLOGY	175	3%	\$8,230K	\$47,027	
UNCATEGORIZED	940	2%	\$6,338K	\$6,742	

High Cost Case Spend Distribution





See Trend

Total Cost of Care Overview for Δ]		Group NA	HealthPartners Product COMMERCIAL
Clinic: All Primary Care Specialty: All		Entity All	Condition OVERALL
Episode Treatment Classification Summary Rolling 12 Months: April 2021 through March 2022	-Episodes ending within the TCOC reporting period -Episode spend inlcudes: Clinics, Hospitals, RX and Referral Providers -Indexed to Metro Average	Clinic All	Specialty All

Cost or Episodes

PI

RUI

TCI

ETG

Performance Results Specialty: All

ETG: All

2.00


1.00


0.00

TCI

PI Savings

Select a Specialty or ETG to view performance results





Vendor List	All
Entity Name	% of Spend
	7.3%
	5.2%
	3.6%
	2.6%
	2.2%
	2.0%
	1.6%
	1.6%
	1.4%

Total Cost (\$\$)

20M

30M


40M

1.3%

Episodes: 416,120

Total Spend: \$676,000,000

Sort by Total Cost



1.12

10M